Adjuvant weekly girentuximab following nephrectomy for high-risk renal cell carcinoma: the ARISER randomized clinical trial.
Authors
Chamie, KDonin, N
Klöpfer, P
Bevan, P
Fall, B
Wilhelm, O
Störkel, S
Said, J
Gambla, M
Hawkins, Robert E
Jankilevich, G
Kapoor, A
Kopyltsov, E
Staehler, M
Taari, K
Wainstein, A
Pantuck, A
Belldegrun, A
Issue Date
2016-10-27
Metadata
Show full item recordAbstract
Girentuximab is a chimeric monoclonal antibody that binds carbonic anhydrase IX, a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC). Its safety and activity in phase 2 studies prompted investigation into its use as adjuvant monotherapy in participants with high-risk ccRCC.Citation
Adjuvant weekly girentuximab following nephrectomy for high-risk renal cell carcinoma: the ARISER randomized clinical trial. 2016 JAMA OncolJournal
JAMA OncologyDOI
10.1001/jamaoncol.2016.4419PubMed ID
27787547Type
ArticleLanguage
enISSN
2374-2445ae974a485f413a2113503eed53cd6c53
10.1001/jamaoncol.2016.4419
Scopus Count
Collections
Related articles
- Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.
- Authors: Haas NB, Manola J, Dutcher JP, Flaherty KT, Uzzo RG, Atkins MB, DiPaola RS, Choueiri TK
- Issue date: 2017 Sep 1
- Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
- Authors: Motzer RJ, Ravaud A, Patard JJ, Pandha HS, George DJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Casey M, Serfass L, Pantuck AJ, Staehler M
- Issue date: 2018 Jan
- Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
- Authors: Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Martini JF, Ramaswamy K, Casey M, Staehler M, Patard JJ, S-TRAC Investigators.
- Issue date: 2016 Dec 8
- Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
- Authors: Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee JL, Melichar B, Rini BI, Choueiri TK, Zemanova M, Wood LA, Reaume MN, Stenzl A, Chowdhury S, Lim HY, McDermott R, Michael A, Bao W, Carrasco-Alfonso MJ, Aimone P, Voi M, Doehn C, Russo P, Sternberg CN, PROTECT investigators.
- Issue date: 2017 Dec 10
- Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
- Authors: Sun M, Marconi L, Eisen T, Escudier B, Giles RH, Haas NB, Harshman LC, Quinn DI, Larkin J, Pal SK, Powles T, Ryan CW, Sternberg CN, Uzzo R, Choueiri TK, Bex A
- Issue date: 2018 Nov